Instruction for use: Choriogonadotropin alfa (Choriogonadotropinum alfa)

Pharmacological group

Hormones of the hypothalamus, pituitary gland, gonadotropins and their antagonists

CAS Code

177073-44-8

Pharmacotherapy

Luteinizing agent - recombinant chorioradotropin alfa, has the same amino acid sequence as the human HG contained in the urine. It binds transmembrane LH receptors on the surface of teca cells and granular cells of the ovary. Causes initiation of oocyte meiosis, rupture of follicles (ovulation), formation of a yellow body, production of progesterone and estradiol by a yellow body.

Pharmacokinetics

With n / to the introduction of absolute bioavailability - 40%, T1 / 2 - about 30 hours.

Indication

Induction of multiple maturation of follicles (superovulation) during assisted reproductive technologies, incl. For IVF. Induction of the final maturation of follicles and luteinization after stimulation with gonadotropins. Induction of ovulation and luteinization at the end of stimulation of follicle growth during anovulatory or oligovulatory infertility.

Contraindications

Hypersensitivity, tumors of the hypothalamus and pituitary gland, ovarian neoplasms or cysts not associated with polycystic ovary, vaginal bleeding of unknown origin, ovarian, uterine or breast cancer, ectopic pregnancy for 3 previous months, thromboembolism, primary ovarian insufficiency, pregnancy-incompatible birth defects Development of genital organs and uterine fibroids, postmenopause.

Precautions

Severe systemic diseases that can worsen during pregnancy.

Dosing

PC. Induction of multiple maturation of follicles (superovulation) during assisted reproductive technologies, incl. For IVF, induction of final follicular maturation and luteinization after stimulation with gonadotropin preparations: 250 mcg once every 24-48 hours after the last administration of FSH or LH after reaching the optimum level of follicle development.

With anovulatory or oligovulatory infertility for induction of ovulation and luteinization at the end of stimulation of follicle growth: 250 μg once 24-48 hours after the last administration of FSH or LH after reaching the optimal level of follicle development. It is recommended to have sexual intercourse on the day of drug administration and the next day.

Side effect

From the side of the central nervous system: headache, rarely - depression, irritability, anxiety.

From the digestive system: nausea, vomiting, abdominal pain, rarely - diarrhea.

On the part of the reproductive system: a syndrome of hyperstimulation of the ovaries, rarely - severe severity, tenderness of the mammary glands.

Local reactions: pain at the injection site.

Other: a feeling of fatigue.

Overdose

Symptoms: Ovarian hyperstimulation syndrome: the formation of large ovarian cysts with the risk of their rupture (perforation), ascites symptoms and circulatory disorders.

Treatment: cancellation of the drug. It is recommended to refrain from sexual contact or use barrier methods of contraception for at least 4 days.

Special instructions

Each bottle is for single use only.

Before the beginning of treatment it is necessary to establish the causes of infertility in the patient and her partner and to assess the presumed risk factors for the onset of pregnancy. Especially it is necessary to take into account the symptoms of hypothyroidism, adrenal insufficiency, hyperprolactinemia, the presence of tumors of the hypothalamic-pituitary system, and specific therapy methods used.

In the process of stimulation of the ovaries, the patients are at risk of developing the ovarian hyperstimulation syndrome because of the simultaneous ripening of a large number of follicles. The syndrome of severe ovarian hyperstimulation can become a serious complication of stimulation. In order to reduce the risk of hyperstimulation syndrome in stimulating the growth of follicles, careful monitoring of ovarian response with ultrasound and the determination of the concentration of estradiol in the blood before and during the course of treatment are recommended.

In comparison with natural fertilization, the risk of multiple pregnancies increases during stimulation.

Administration of the drug may affect the concentration of human HC in the blood serum and urine for 10 days and lead to a false positive reaction during the pregnancy test.

During the therapy, slight stimulation of thyroid function is possible.